← All trials
NCT03745963
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 19, 2018
- Primary completion
- Dec 31, 2020
- Completion date
- Mar 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 126
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Dalhousie UniversityLead sponsor
- Dalhousie UniversityReponsible party - principal investigator
- Dalhousie UniversityOverall official - principal investigator
- Nova Scotia Health Research FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.